Schoepfer, Alain M.; Vavricka, Stephan R.; Binek, Janek; Felley, Christian; Geyer, Martin; Manz, Michael; Rogler, Gerhard; de Saussure, Philippe; Sauter, Bernhard; Seibold, Frank; Straumann, Alex; Michetti, Pierre (2010). Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohnʼs disease population. Inflammatory bowel diseases, 16(6), pp. 933-938. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1002/ibd.21127
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
0054725-201006000-00009.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (178kB) | Request a copy |
Switzerland was the first country to approve certolizumab pegol (Cimzia, CZP) for the treatment of patients with moderate to severe Crohn's disease (CD) in September 2007. This phase IV study aimed to evaluate the efficacy and safety of CZP in a Swiss multicenter cohort of practice-based patients.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology |
UniBE Contributor: |
Seibold, Frank Werner |
ISSN: |
1078-0998 |
Publisher: |
Lippincott Williams & Wilkins |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:07 |
Last Modified: |
21 Dec 2022 15:37 |
Publisher DOI: |
10.1002/ibd.21127 |
PubMed ID: |
20014021 |
Web of Science ID: |
000278514100009 |
BORIS DOI: |
10.48350/83 |
URI: |
https://boris.unibe.ch/id/eprint/83 (FactScience: 195328) |
Actions (login required)
 |
Edit item |